ArticleFuture oncology (London, England)2024

Cost-effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan.

Saaya Tsutsué et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.